The new finding from this study is that monoclonal NGF antibodies have the highest efficacy for pain relief and functional improvement, exceeding that of selective COX-2 inhibitors, NSAIDs, and weak opioids (tramadol), all of which are recommended in the 2019th American College of Rheumatology/Arthritis Foundation Guideline. The gene discussed is NGF; the disease is arthritic joint disease.